<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01743404</url>
  </required_header>
  <id_info>
    <org_study_id>IAR-INFL</org_study_id>
    <nct_id>NCT01743404</nct_id>
  </id_info>
  <brief_title>Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis</brief_title>
  <official_title>Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Atherosclerosis Research, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Atherosclerosis Research, Russia</source>
  <oversight_info>
    <authority>Russia: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the anti-atherosclerotic effect of long-term
      anti-inflammatory therapy (Inflaminat) in asymptomatic participants with subclinical
      atherosclerosis of carotid arteries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>B-mode ultrasound of carotid arteries</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Variation of intima-media thickness of common carotid arteries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of serum atherogenicity</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change of the ability of serum to induce cholesterol accumulation in cultured cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Inflaminat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflaminat 500 mg tablet by mouth three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500 mg tablet by mouth three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inflaminat</intervention_name>
    <arm_group_label>Inflaminat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic Inflaminat 500 mg tablet</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 40 to 70 years

          -  Subclinical carotid atherosclerosis detected by B-mode ultrasound (increased
             intima-media thickness 1000-2000 mcm)

          -  Arterial normotension or mild arterial hypertension (systolic blood pressure &lt;160 mm
             Hg, diastolic blood pressure &lt;90 mm Hg)

          -  Absence of chronic diseases demanding permanent drug administration (more than 2
             month per year)

        Exclusion Criteria:

          -  Personal history of stroke or transient ischemic attacks

          -  Chronic diseases demanding drug administration more than during 2 month per year

          -  Individual intolerance of Inflaminat or appearance of side effects
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Igor Sobenin, MD</last_name>
    <phone>+79263590050</phone>
    <email>igor.sobenin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ekaterina Chernova</last_name>
    <phone>+79166647123</phone>
    <email>katrincorde@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Atherosclerosis Research</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Sobenin, MD</last_name>
      <phone>+79263590050</phone>
      <email>igor.sobenin@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ekaterina Chernova</last_name>
      <phone>+79166647123</phone>
      <email>katrincorde@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>December 4, 2012</lastchanged_date>
  <firstreceived_date>December 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>inflammation</keyword>
  <keyword>intima-media thickness</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
